EP950 Predictive value of biomarkers during chemotherapy in patients with epithelial malignant ovarian cancer. (1st November 2019)

• Record Type: Journal Article
• Authors: Parpinel, G; Potenza, E; Macchi, C; Carapezzi, A; Laudani, ME; Fuso, L; Zola, P
• Is Part Of: International journal of gynecological cancer. Volume 29(2019)Supplement 4
• Page Start: A507
• Page End: A507
• Publication Date: 2019-11-01
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2019-ESGO.996
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Introduction/Background: At present there is no predictive value univocally associated with the success of chemotherapy in the treatment of epithelial ovarian cancer. Biomarkers produced by ovarian cancer (HE4 and Ca125) could have a good prognostic significance. The aim of this study is to prove the ability of biomarkers to identify patients with the highest risk of not optimal response during the chemotherapy and to predict which patients will most probably develop recurrence of disease. Methodology: We analyzed 78 patients with EOC (epithelial ovarian cancer) who underwent surgery in the biennium 2016–2017. All the patients performed chemotherapy after surgery or interval debulking surgery following neoadjuvant therapy. Serum levels of HE4 and Ca125 were measured at the diagnosis and at each cycle of chemotherapy. We established the degree of response to the treatment by CT-scan and the patients were followed up (FU median: 10 months). The parameters PFS (performance free survival) and DFS (disease free survival) were related to serum levels of biomarkers. Results: The average markers values became both negative at the fourth cycle in the patients with good response to chemotherapy. HE4 rise compared earlier than Ca125. The parameters that best correlated with a long PFS were: negativization of the marker after the third cycle of chemotherapy (HE4: OR 5.5; Ca125: OR 9.1) and biomarker serum levels lower than the mean value in the affected population at the time of diagnosis (HE4: OR 3.4; Ca125: OR 3.7). Conclusion: Based on the data obtained from this study we can conclude that the monitoring of HE4 and Ca125 during chemotherapy, especially at the third cycle, is recommended, because their variation is a good prognostic factor. Disclosure: Nothing to disclose.